Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ethoxzolamide is a sulfonamide small molecule that acts as a carbonic anhydrase inhibitor. It is used primarily in the treatment of glaucoma and duodenal ulcers and as a diuretic. Ethoxzolamide may also be used in some forms of epilepsy. Its mechanism involves inhibition of carbonic anhydrase enzymes (notably carbonic anhydrase I), which decreases reabsorption of water, sodium, potassium, and bicarbonate in the proximal renal tubules—leading to its diuretic effect—and reduces intraocular pressure by decreasing aqueous humor production in the eye. Inhibition within the central nervous system increases seizure threshold[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ethoxzolamide.